Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.37871
Abstract: Key Points Question Is circulating tumor cell (CTC) count at the start of treatment associated with overall survival in metastatic hormone-sensitive prostate cancer (mHSPC)? Findings In this prognostic study of 1313 men initiating systemic hormonal… read more here.
Keywords: tumor cell; survival; metastatic hormone; count ... See more keywords
Treatment Patterns and Survival Among Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2025.9433
Abstract: Key Points Question How has treatment for and survival of metastatic hormone-sensitive prostate cancer (mHSPC) changed over time? Findings In a cross-sectional study of 6216 veterans with de novo mHSPC, the use of combination therapy… read more here.
Keywords: veterans novo; sensitive prostate; metastatic hormone; prostate cancer ... See more keywords
Controversies in metastatic hormone‐sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2025 at "Cancer"
DOI: 10.1002/cncr.70030
Abstract: Metastatic hormone‐sensitive prostate cancer (mHSPC) is an incurable phase of prostate cancer. Diagnostic tools and management strategies for this complex disease are expanding. Despite these advances, more therapies may not be the optimal approach for… read more here.
Keywords: cancer; prostate; sensitive prostate; metastatic hormone ... See more keywords
Risk classification by pathological and biochemical prognostic factors determined by extensive exploration for metastatic hormone sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2025 at "World Journal of Urology"
DOI: 10.1007/s00345-025-05862-4
Abstract: To determine prognostic parameters, we extensively examined whether physical, biochemical, and histological factors were associated with clinical outcomes in metastatic hormone sensitive prostate cancer (mHSPC) patients. A total 822 mHSPC patients were retrospectively investigated and… read more here.
Keywords: classification; risk classification; metastatic hormone; risk ... See more keywords
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.08.010
Abstract: AIM Androgen deprivation therapy (ADT) has long been the gold standard for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Clinical trials have demonstrated significant survival benefits when docetaxel (DOC) or abiraterone acetate (AA) and prednisone… read more here.
Keywords: prostate; hormone sensitive; metastatic hormone; sensitive prostate ... See more keywords
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "European urology oncology"
DOI: 10.1016/j.euo.2019.01.004
Abstract: BACKGROUND Following the recent publication of results from randomized trials that have demonstrated a survival benefit for the addition of docetaxel or abiraterone acetate to androgen deprivation therapy (ADT) in the treatment of metastatic prostate… read more here.
Keywords: adt; treatment; hormone sensitive; metastatic hormone ... See more keywords
Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2017.09.029
Abstract: Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition… read more here.
Keywords: abiraterone acetate; prostate cancer; hormone sensitive; metastatic hormone ... See more keywords
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-51389-w
Abstract: The objective of this study is to compare the efficacy of apalutamide and bicalutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We retrospectively collected the data of about 330… read more here.
Keywords: androgen deprivation; therapy; metastatic hormone; group ... See more keywords
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Sign Up to like & getrecommendations! Published in 2021 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.1055/s-0041-1729725
Abstract: Androgen deprivation therapy (ADT) combined with docetaxel or antiandrogens (abiraterone, enzalutamide, or apalutamide) improved the outcomes in men with metastatic hormone-sensitive prostate cancer (mHSPC). When multiple options are available, the dilemma remains how to choose… read more here.
Keywords: metastatic hormone; sensitive prostate; prostate cancer; hormone sensitive ... See more keywords
Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Urology"
DOI: 10.1080/21681805.2022.2028006
Abstract: Abstract Aim/Background The aim of this study was to evaluate the feasibility and efficacy, in terms of overall survival, of intensified upfront systemic therapy in patients with metastatic hormone-sensitive prostate cancer who lived in rural… read more here.
Keywords: metastatic hormone; feasibility efficacy; therapy; early docetaxel ... See more keywords
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdy071
Abstract: Abstract Background Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not… read more here.
Keywords: systemic treatment; network; treatment; metastatic hormone ... See more keywords